Craig — this constant “support with a shrug” routine is tired. Management silence during regulatory and partner discussions is normal; it doesn’t mean nothing is happening. The oncology posters from Munich and Barcelona showed objective responses in tough, late-line patients with a clear CCR5 immunologic rationale. Small N ≠ no signal — it’s the reason you advance to the next phase.

As for “proven cure” being overstated — fine, drop the word “cure.” The accurate statement is: strong emerging clinical signal and a registrational path in defined cohorts. That’s the truth, and it’s backed by data.

So either bring counter-data or stop circling back to the same vague doubt. This board deserves evidence, not recycled soft bashing.

I’m sure you’ll be deleted otherwise so put up or shut up